WilmerHale Represents Generation Bio in $100M Series B Financing

Download IconDownload Print IconPrint

WilmerHale Represents Generation Bio in $100M Series B Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing. Proceeds will be used to move Generation Bio's first two therapeutic candidates through Investigational New Drug enabling studies and to advance additional programs targeting genetic diseases of the retina, central nervous system and lungs. This follows on the heels of the company's previously announced $25 million Series A financing.

The WilmerHale team representing Generation Bio includes Stuart Falber, Stephanie Singer and Brett Bromann, with licensing counsel from Steve Barrett.

Read the press release announcing this news for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel